Exelixis (EXEL) Tops Q4 EPS by 13c

Go back to Exelixis (EXEL) Tops Q4 EPS by 13c

Exelixis (EXEL) PT Raised to $33 at Needham & Company

February 13, 2019 10:52 AM EST

Needham & Company analyst Chad Messer raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $30.00) while maintaining a Buy rating.

Messer commented, "Exelixis reported $176M in Cabo sales in 4Q:18, an 8% increase q/q. FY18 Cabo sales were $619M, a 44% increase... More

Exelixis (EXEL) PT Raised to $33 at Guggenheim Following 4Q

February 13, 2019 10:01 AM EST

Guggenheim analyst Michael Schmidt raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $31.00) while maintaining a Buy rating following the company's 4Q earnings report. EXEL reported 4Q18 revenue of $229M, 22% above Street consensus of $188M. Non-GAAP diluted EPS was 0.37, driven mostly by a... More

Exelixis (EXEL) PT Lowered to $31 at Oppenheimer

February 13, 2019 7:58 AM EST

Oppenheimer analyst Silvan Tuerkcan lowered the price target on Exelixis (NASDAQ: EXEL) to $31.00 (from $40.00) while maintaining a Outperform rating.

The analyst commented, "EXEL reported 4Q $176.2M revenue beating $170.0M consensus driven by Cabometyx sales of $171.6M vs $166M consensus. Cabometyx sales grew... More